Jun-Ning Liu
Ji-Jiang Li
Peng-Sheng Yi
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
by Liu J-N, Li J-J, Yan S, Zhang G-N and Yi P-S (2023) Front. Oncol. 13:1074793. doi: 10.3389/fonc.2023.1074793
Error in Figure
In the published article, there was an error in Figure 2 as published. The two labels “Favours [LEN+TACE]” and “Favours [SOR+TACE]” located on the left and right below the X-axis, should read “Favours [SOR+TACE]” and “Favours [LEN+TACE]” respectively. The corrected Figure 2 and its caption “Forest plots for the comparison of (A) objective response rate (ORR) and disease control rate (DCR), and (B) complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)” appear below.
FIGURE 2
Figure 2 Forest plots for the comparison of (A) objective response rate (ORR) and disease control rate (DCR), and (B) complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hepatocellular carcinoma (HCC), lenvatinib, sorafenib (nexavar), transarterial chemoembolization (TACE), combination therapy
Citation: Liu J-N, Li J-J, Yan S, Zhang G-N and Yi P-S (2023) Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front. Oncol. 13:1233247. doi: 10.3389/fonc.2023.1233247
Received: 01 June 2023; Accepted: 14 June 2023;
Published: 22 June 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Liu, Li, Yan, Zhang and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng-Sheng Yi, bGl1anVubmluZzk4QDE2My5jb20=